# An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

> **NCT05592483** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 78 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** None (Observational Study)

## Key facts

- **NCT ID:** NCT05592483
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-07
- **Primary completion:** 2024-05-29
- **Final completion:** 2024-05-29
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** The DESTINY-Breast RESPOND study was terminated early due to start-up delays and slow enrolment, despite extensive mitigation. Operational challenges alone prevent study continuation and were not related to any product or patient safety concerns.
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05592483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05592483, "An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05592483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*